P.4.c.002 Quetiapine augmentation of SSRIs for treatment refractory social anxiety disorder

Effect of quetiapine vs. placebo on response to two virtual public speaking exposures in individuals with social phobia

“…As noted earlier, the dose of quetiapine used in this study is within the bounds of current clinical practice (range 25-200 mg) in managing anxiety (Philip et al, 2008;Rowe, 2007). Regarding SAD particularly, quetiapine doses up to 300 mg/day (Schutters et al, 2005) and as low as 56 mg/day (Kinrys et al, 2007) have appeared to be therapeutic. However, consistent with our findings, the one double-blind placebo-controlled study addressing this question was negative (dose = 147 AE 105 mg) (Vaishnavi et al, 2007).…”

“…For example, an open-label trial of quetiapine (flexible dosing 150-300 mg/day) resulted in significant reductions in SAD symptoms (Schutters, van Megen, & Westenberg, 2005). SAD patients who were partial or nonresponders to SSRI therapy reported significant reductions in anxiety in response to adjunctive quetiapine (55.7 AE 31.2 mg daily) (Kinrys et al, 2007). Similarly, significant reductions in anxiety have been reported when using quetiapine (maximum daily dose of 300 mg) as adjunctive therapy with stable SSRI dosing for mixed mood and anxiety disordered patients (Adson, Kushner, Eiben, & Schulz, 2004) and as monotherapy for anxiety symptoms in both GAD and MDD (Bandelow et al, 2007;Brawman-Mintzer, 2006).…”